Linda Bain, Chief Financial Officer at Avalanche Biotechnologies, Inc. ([AAVL]), sold 715 shares at $34.91 ($25K) on 2015-05-11, disclosed to the SEC on 2015-05-12.
Scheduled sale ($25k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| CDAK | SELL | 2023-01-23 | $1K | — | Filing → |
| [AAVL] | SELL | 2015-06-15 | $140K | — | Filing → |
| [AAVL] | SELL | 2015-05-13 | $10K | — | Filing → |